#1 Clinical Trials Search in Europe

Treg02

A groundbreaking clinical trial is underway to investigate the use of Treg02, a novel drug containing regulatory T cells, as a potential therapy for kidney transplant patients. This Phase I/IIa study aims to evaluate the safety and effectiveness of Treg02 when used alongside standard immunosuppressive treatments. The trial focuses on patients receiving deceased-donor kidney transplants and explores how Treg02 might improve long-term outcomes for recipients.

Table of Contents

What is TREG02?

TREG02 is a new medical treatment being studied for patients who have received a kidney transplant. It is classified as an Advanced Therapy Medicinal Product (ATMP), which means it’s a cutting-edge treatment that uses biological materials from the patient’s own body[1]. Specifically, TREG02 is a solution for injection that contains regulatory T cells, also known as Tregs.

How Does TREG02 Work?

TREG02 works by using the patient’s own regulatory T cells, which are a type of immune cell that helps control the immune system’s response. In the context of kidney transplants, these cells are specially prepared and then given back to the patient. The goal is to help the patient’s body accept the new kidney without rejecting it, potentially reducing the need for other immunosuppressive drugs[1].

Clinical Trial Details

The clinical trial for TREG02 is called “ProTreg” and is currently in Phase I/IIa. This means it’s in the early stages of testing in humans. The main objectives of this trial are to:

  1. Determine if TREG02 is safe for kidney transplant recipients
  2. Investigate if TREG02 can help the body accept the transplanted kidney
  3. Gather initial data on whether TREG02 could allow for a reduction in other immunosuppressive medications

This trial is specifically for patients who have received a kidney from a deceased donor[1].

Who Can Participate in the TREG02 Trial?

The trial has specific criteria for who can participate. Some key points include:

  • Patients aged 18-65 with severe kidney disease (GFR < 15 ml/min x 1.73 m²)
  • Patients who are about to receive a kidney transplant from a deceased donor
  • Patients who have not had any previous organ transplants
  • Patients without certain health conditions like HIV, hepatitis, or cancer

There are many other specific criteria that doctors will use to determine if someone is eligible for the trial[1].

Potential Benefits of TREG02

While it’s important to remember that TREG02 is still in the testing phase, researchers hope it could offer several benefits:

  • Reduced risk of the body rejecting the transplanted kidney
  • Potential to decrease the amount of other immunosuppressive drugs needed
  • Improved long-term outcomes for kidney transplant patients

The trial will measure these potential benefits in various ways, including monitoring for signs of kidney rejection and assessing kidney function over time[1].

Safety Considerations

As with any new medical treatment, safety is a top priority. The trial will closely monitor patients for any side effects or complications. Some specific areas of focus include:

  • Immediate reactions to the TREG02 injection
  • Signs of over-suppression of the immune system, which could increase the risk of infections
  • Long-term effects, such as the potential development of autoimmune disorders or certain types of cancer

It’s important to note that these are potential risks that the researchers will be watching for, not confirmed side effects of TREG02[1].

Conclusion

TREG02 represents an exciting new approach to helping kidney transplant patients. By using the body’s own regulatory T cells, it aims to improve transplant outcomes and potentially reduce the need for other immunosuppressive drugs. However, it’s still in the early stages of testing, and more research is needed to fully understand its effects and benefits. If you’re a kidney transplant patient and are interested in learning more about TREG02, talk to your doctor about whether you might be eligible for this or similar clinical trials.

Aspect Details
Study Type Phase I/IIa open-label, single ascending dose study
Main Objective Evaluate safety and tolerability of Treg02 in kidney transplant recipients
Target Population Adults (18-65) with chronic renal insufficiency eligible for kidney transplant
Primary Endpoints Acute toxicity, over-suppression of immune system, chronic toxicity, biopsy-confirmed acute rejection
Secondary Endpoints Prevention of acute rejection, subclinical rejection, chronic graft dysfunction, post-transplant complications, quality of life
Drug Information Treg02, solution for injection, containing regulatory T cells

FAQ

  • What is Treg02? Treg02 is a new drug containing regulatory T cells, which are a type of immune cell. It is being studied as a potential therapy to help kidney transplant patients accept their new organ and possibly reduce the need for other immunosuppressive medications.
  • Who can participate in this clinical trial? The trial is open to adults aged 18-65 with chronic kidney failure who are eligible for a kidney transplant. Participants must meet specific health criteria and be willing to follow the study protocol.
  • What are the main goals of this study? The primary goals are to determine if Treg02 is safe for kidney transplant recipients, to see if it helps the body accept the transplanted kidney, and to gather initial data on whether it could allow for reduced use of other immunosuppressive drugs.
  • How is Treg02 given to patients? Treg02 is administered as a solution for injection. The exact details of how and when it's given will be explained to participants by the study team.
  • What are the potential benefits and risks of participating? Potential benefits include improved transplant outcomes and possibly reduced need for other immunosuppressive drugs. Risks may include reactions to the infusion, over-suppression of the immune system, or other unforeseen side effects. The study team will closely monitor participants for any adverse effects.

Ongoing Clinical Trials on Treg02

  • Safety Study of Regulatory T Cells (Treg02) in Patients After Kidney Transplant

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Safety Study of Regulatory T Cells (Treg02) and Tacrolimus Discontinuation in Adult Liver Transplant Recipients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Regulatory T cells (Tregs): A type of immune cell that helps control the immune system's response, potentially preventing rejection of transplanted organs.
  • Immunosuppressive therapy: Medications used to lower the body's immune response to prevent rejection of transplanted organs.
  • Biopsy-confirmed acute rejection (BCAR): A situation where a tissue sample from the transplanted kidney shows signs of the body rejecting the organ.
  • Glomerular filtration rate (GFR): A measure of how well the kidneys are filtering waste from the blood.
  • Panel-reactive antibodies (PRA): A blood test that measures how reactive a person's immune system might be against potential donor organs.
  • Cytomegalovirus (CMV): A common virus that can cause serious problems in people with weakened immune systems, such as transplant recipients.
  • Epstein-Barr virus (EBV): Another common virus that can be more serious in people with suppressed immune systems.
  • Karnofsky score: A scale used to measure a person's overall health and ability to perform daily activities.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-treg02-with-tacrolimus-and-mycophenolate-mofetil-for-kidney-transplant-patients/